XPO1 and diffuse large B-cell lymphoma: Selinexor, a selective XPO1 inhibitor, has demonstrated clinical activity in 40% of RT-DLBCL patients who were refractory to prior chemotherapy regimens (two out of five patients achieved partial responses), highlighting XPO1 as a potential therapeutic target in TP53-mutated RT [26].